SEARCH

SEARCH BY CITATION

References

  • 1
    Ganem D, Schneider RJ. Hepadnaviridae and their replication. In: KnipeDM, HowleyPM, GriffinDE, LambRA, RoizmanB, MartinMA, StrausSE. Fields Virology. 4th ed. Philadelphia: Lippincott-Raven Publishers, 2001;29232970.
  • 2
    Chang C, Enders G, Sprengel R, Peters N, Varmus HE, Ganem D. Expression of the precore region of an avian hepatitis B virus is not required for viral replication. J Virol 1987; 61:33223325.
  • 3
    Schlicht HJ, Salfeld J, Schaller H. The duck hepatitis B virus pre-C region encodes a signal sequence which is essential for synthesis and secretion of processed core proteins but not for virus formation. J Virol 1987; 61:37013709.
  • 4
    Chen Y, Kew MC, Hornbuckle WE, Tennant BC, Cote PJ, Gerin JL, Purcell RH, et al. The precore gene of the woodchuck hepatitis virus genome is not essential for viral replication in the natural host. J Virol 1992; 66:56825684.
  • 5
    Salfeld J, Pfaff E, Noah M, Schaller H. Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus. J Virol 1989; 63:798808.
  • 6
    Conway JF, Cheng N, Zlotnick A, Stahl SJ, Wingfield PT, Belnap DM, Kanngiesser U, et al. Hepatitis B virus capsid: localization of the putative immunodominant loop (residues 78 to 83) on the capsid surface, and implications for the distinction between c and e-antigens. J Mol Biol 1998; 279:11111121.
  • 7
    Crowther RA, Kiselev NA, Bottcher B, Berriman JA, Borisova GP, Ose V, Pumpens P. Three-dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy. Cell 1994; 77:943950.
  • 8
    Wasenauer G, Kock J, Schlicht H-J. A cysteine and a hydrophobic sequence in the noncleaved portion of the pre-C leader peptide determine the biophysical properties of the secretory core protein (HBe protein) of human hepatitis B virus. J Virol 1992; 66:53385346.
  • 9
    Milich DR, Jones JE, Hughes JL, Maruyama T, Price J, Melhado I, Jirik F. Extrathymic expression of the intracellular hepatitis B core antigen results in T cell tolerance in transgenic mice. J Immunol 1994; 152:455466.
  • 10
    Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci U S A 1990; 87:65996603.
  • 11
    Terazawa S, Kojima M, Yamanaka T, Yotsumoto S, Okamoto H, Tsuda F, Miyakawa Y, et al. Hepatitis B virus mutants with precore-region defects in two babies with fulminant hepatitis and their mothers positive for antibody to hepatitis B e antigen. Pediatr Res 1991; 29:59.
  • 12
    Baumert TF, Liang TJ. Precore mutants revisited. Hepatology 1996; 23:184186.
  • 13
    Gunther S, Meisel H, Reip A, Miska S, Kruger DH, Will H. Frequent and rapid emergence of mutated pre-C sequences in HBV from e-antigen positive carriers who seroconvert to anti-HBe during interferon treatment. Virology 1992; 187:271279.
  • 14
    Li JS, Tong SP, Wen YM, Vitvitski L, Zhang Q, Trepo C. Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: possible contribution of a single nucleotide in the precore region. J Virol 1993; 67:54025410.
  • 15
    Rodriguez-Frias F, Buti M, Jardi R, Cotrina M, Viladomiu L, Esteban R, Guardia J. Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations. Hepatology 1995; 22:16411647.
  • 16
    Okamoto H, Yotsumoto S, Akahane Y, Yamanaka T, Miyazaki Y, Sugai Y, Tsuda F, et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990; 64:12981303.
  • 17
    Takeda K, Akahane Y, Suzuki H, Okamoto H, Tsuda F, Miyakawa Y, Mayumi M. Defects in the precore region of the HBV genome in patients with chronic hepatitis B after sustained seroconversion from HBeAg to anti-HBe induced spontaneously or with interferon therapy. Hepatology 1990; 12:12841289.
  • 18
    Akahane Y, Yamanaka T, Suzuki H, Sugai Y, Tsuda F, Yotsumoto S, Omi S, et al. Chronic active hepatitis with hepatitis B virus DNA and antibody against e antigen in the serum. Disturbed synthesis and secretion of e antigen from hepatocytes due to a point mutation in the precore region. Gastroenterology 1990; 99:11131119.
  • 19
    Bonino F, Rosina F, Rizzetto M, Rizzi R, Chiaberge E, Tardanico R, Callea F, et al. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986; 90:12681273.
  • 20
    Angus PW, Locarnini SA, McCaughan GW, Jones RM, McMillan JS, Bowden DS. Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation. Hepatology 1995; 21:1418.
  • 21
    Akarca US, Greene S, Lok AS. Detection of precore hepatitis B virus mutants in asymptomatic HBsAg-positive family members. Hepatology 1994; 19:13661370.
  • 22
    Chu CM, Yeh CT, Lee CS, Sheen IS, Liaw YF. Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion. J Clin Microbiol 2002; 40:1621.
  • 23
    Hamasaki K, Nakata K, Nagayama Y, Ohtsuru A, Daikoku M, Taniguchi K, Tsutsumi T, et al. Changes in the prevalence of HBeAg-negative mutant hepatitis B virus during the course of chronic hepatitis B. Hepatology 1994; 20:814.
  • 24
    Maruyama T, Kuwata S, Koike K, Iino S, Yasuda K, Yotsuyanagi H, Moriya K, et al. Precore wild-type DNA and immune complexes persist in chronic hepatitis B after seroconversion: no association between genome conversion and seroconversion. Hepatology 1998; 27:245253.
  • 25
    Brunetto MR, Giarin MM, Oliveri F, Chiaberge E, Baldi M, Alfarano A, Serra A, et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A 1991; 88:41864190.
  • 26
    Loriot MA, Marcellin P, Talbodec N, Guigonis V, Gigou M, Boyer N, Bezeaud A, et al. Low frequency of precore hepatitis B virus mutants in anti-hepatitis B e-positive reactivation after loss of hepatitis B e antigen in patients with chronic hepatitis B. Hepatology 1995; 21:627631.
  • 27
    Carman WF, Fagan EA, Hadziyannis S, Karayiannis P, Tassopoulos NC, Williams R, Thomas HC. Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis. Hepatology 1991; 14:219222.
  • 28
    Raimondo G, Tanzi E, Brancatelli S, Campo S, Sardo MA, Rodino G, Pernice M, et al. Is the course of perinatal hepatitis B virus infection influenced by genetic heterogeneity of the virus? J Med Virol 1993; 40:8790.
  • 29
    Mphahlele MJ, Shattock AG, Boner W, Quinn J, McCormick PA, Carman WF. Transmission of a homogenous hepatitis B virus population of A1896-containing strains leading to mild resolving acute hepatitis and seroconversion to hepatitis B e antigen antibodies in an adult. Hepatology 1997; 26:743746.
  • 30
    Fagan EA, Smith PM, Davison F, Williams R. Fulminant hepatitis B in successive female sexual partners of two anti-HBe-positive males. Lancet 1986; 2:538540.
  • 31
    Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben-Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis B. N Engl J Med 1991; 324:17051709.
  • 32
    Petrosillo N, Ippolito G, Solforosi L, Varaldo PE, Clementi M, Manzin A. Molecular epidemiology of an outbreak of fulminant hepatitis B. J Clin Microbiol 2000; 38:29752981.
  • 33
    Stuyver L, De Gendt S, Cadranel JF, Van Geyt C, Van Reybroeck G, Dorent R, Gandjbachkh I, et al. Three cases of severe subfulminant hepatitis in heart-transplanted patients after nosocomial transmission of a mutant hepatitis B virus. Hepatology 1999; 29:18761883.
  • 34
    Tanaka S, Yoshiba M, Iino S, Fukuda M, Nakao H, Tsuda F, Okamoto H, et al. A common-source outbreak of fulminant hepatitis B in hemodialysis patients induced by precore mutant. Kidney Int 1995; 48:19721978.
  • 35
    Bahn A, Hilbert K, Martine U, Westedt J, von Weizsacker F, Wirth S. Selection of a precore mutant after vertical transmission of different hepatitis B virus variants is correlated with fulminant hepatitis in infants. J Med Virol 1995; 47:336341.
  • 36
    Aye TT, Uchida T, Becker SO, Hirashima M, Shikata T, Komine F, Moriyama M, et al. Variations of hepatitis B virus precore/core gene sequence in acute and fulminant hepatitis B. Dig Dis Sci 1994; 39:12811287.
  • 37
    Friedt M, Gerner P, Lausch E, Trubel H, Zabel B, Wirth S. Mutations in the basic core promoter and the precore region of hepatitis B virus and their selection in children with fulminant and chronic hepatitis B. Hepatology 1999; 29:12521258.
  • 38
    Laskus T, Persing DH, Nowicki MJ, Mosley JW, Rakela J. Nucleotide sequence analysis of the precore region in patients with fulminant hepatitis B in the United States. Gastroenterology 1993; 105:11731178.
  • 39
    Liang TJ, Hasegawa K, Munoz SJ, Shapiro CN, Yoffe B, McMahon BJ, Feng C, et al. Hepatitis B virus precore mutation and fulminant hepatitis in the United States. A polymerase chain reaction-based assay for the detection of specific mutation. J Clin Invest 1994; 93:550555.
  • 40
    Sterneck M, Gunther S, Santantonio T, Fischer L, Broelsch CE, Greten H, Will H. Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation. Hepatology 1996; 24:300306.
  • 41
    Günther S, Piwon N, Iwanska A, Schilling R, Meisel H, Will H. Type, prevalence, and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease. J Virol 1996; 70:83188331.
  • 42
    Laskus T, Rakela J, Nowicki MJ, Persing DH. Hepatitis B virus core promoter sequence analysis in fulminant and chronic hepatitis B. Gastroenterology 1995; 109:16181623.
  • 43
    Okamoto H, Tsuda F, Akahane Y, Sugal Y, Yoshiba M, Moriyama K, Tanaka T, et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994; 68:81028110.
  • 44
    Sato S, Suzuki K, Akahane Y, Akamatsu K, Akiyama K, Yunomura K, Tsuda F, et al. Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med 1995; 122:241248.
  • 45
    Baumert TF, Rogers SA, Hasegawa K, Liang TJ. Two core promoter mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. J Clin Invest 1996; 98:22682276.
  • 46
    Buckwold VE, Xu Z, Chen M, Yen TSB, Ou J-H. Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication. J Virol 1996; 70:58455851.
  • 47
    Moriyama K, Okamoto H, Tsuda F, Mayumi M. Reduced precore transcription and enhanced core-pregenome transcription of hepatitis B virus DNA after replacement of the precore-core promoter with sequences associated with e antigen-seronegative persistent infections. Virology 1996; 226:269280.
  • 48
    Pult I, Chouard T, Wieland S, Klemenz R, Yaniv M, Blum HE. A hepatitis B virus mutant with a new hepatocyte nuclear factor 1 binding site emerging in transplant-transmitted fulminant hepatitis B. Hepatology 1997; 25:15071515.
  • 49
    Sterneck M, Kalinina T, Gunther S, Fischer L, Santantonio T, Greten H, Will H. Functional analysis of HBV genomes from patients with fulminant hepatitis. Hepatology 1998; 28:13901397.
  • 50
    Gunther S, Piwon N, Jung A, Iwanska A, Schmitz H, Will H. Enhanced replication contributes to enrichment of hepatitis B virus with a deletion in the core gene. Virology 2000; 273:286299.
  • 51
    Kalinina T, Riu A, Fischer L, Will H, Sterneck M. A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis. Hepatology 2001; 34:385394.
  • 52
    Lambert C, Nassal MVelhagen I, Zentgraf H, Schroder CH. Precore-mediated inhibition of hepatitis B virus progeny DNA synthesis. J Virol 1993; 67:37563762.
  • 53
    Guidotti LG, Matzke B, Pasquinelli C, Shoenberer JM, Rogler CE, Chisari FV. The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice. J Virol 1996; 70:70567061.
  • 54
    Schneider R, Fernholz D, Wildner G, Will H. Mechanism, kinetics, and role of duck hepatitis B virus e-antigen expression in vivo. Virology 1991; 182:503512.
  • 55
    Chuang WL, Omata M, Ehata T, Yokosuka O, Hosoda K, Imazeki F, Ohto M. Coinfection study of precore mutant and wild-type hepatitis B-like virus in ducklings. Hepatology 1994; 19:569576.
  • 56
    Tomita T, Yokosuka O, Tagawa M, Saisho H, Tamura S, Fukuda I, Omata M. Decrease of wild-type and precore mutant duck hepatitis B virus replication during lamivudine treatment in white Peking ducks infected with the viruses. J Hepatol 2000; 32:850858.
  • 57
    Zhang YY, Summers J. Enrichment of a precore-minus mutant of duck hepatitis B virus in experimental mixed infections. J Virol 1999; 73:36163622.
  • 58
    Ma Z, Wen Y, Xiong S, Zhai W, He L, Yao X. Experimental study on pathogenicity of precore mutants in Hepadnaviridae. Chin Med J (Engl) 1998; 111:519523.
  • 59
    Cote PJ, Korba BE, Miller RH, Jacob JR, Baldwin BH, Hornbuckle WE, Purcell RH, et al. Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection. Hepatology 2000; 31:190200.
  • 60
    Ogata N, Miller RH, Ishak KG, Purcell RH. The complete nucleotide sequence of a pre-core mutant of hepatitis B virus implicated in fulminant hepatitis and its biological characterization in chimpanzees. Virology 1993; 194:263276.
  • 61
    Milich DR, McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science 1986; 234:13981401.
  • 62
    Bertoletti A, Ferrari C, Fiaccadori F, Penna A, Margolskee R, Schlicht HJ, Fowler P, et al. HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci U S A 1991; 88:1044510449.
  • 63
    Townsend K, Sallberg M, O'Dea J, Banks T, Driver D, Sauter S, Chang SM, et al. Characterization of CD8+ cytotoxic T-lymphocyte responses after genetic immunization with retrovirus vectors expressing different forms of the hepatitis B virus core and e antigens. J Virol 1997; 71:33653374.
  • 64
    Ishikawa T, Kakumu S, Yoshioka K, Yamada M, Tanaka K, Higashi Y, Takayanagi M, et al. Relative immunogenicity of hepatitis B virus-encoded antigens as targets for cytotoxic T-cell response. Immunology 1993; 80:313318.
  • 65
    Kuhober A, Pudollek HP, Reifenberg K, Chisari FV, Schlicht HJ, Reimann J, Schirmbeck R. DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice. J Immunol 1996; 156:36873695.
  • 66
    Jung MC, Diepolder HM, Spengler U, Wierenga EA, Zachoval R, Hoffmann RM, Eichenlaub D, et al. Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol 1995; 69:33583368.
  • 67
    Ferrari C, Penna A, Bertoletti A, Valli A, Antoni AD, Giuberti T, Cavalli A, et al. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990; 145:34423449.
  • 68
    Milich DR, McLachlan A, Stahl S, Wingfield P, Thornton GB, Hughes JL, Jones JE. Comparative immunogenicity of hepatitis B virus core and E antigens. J Immunol 1988; 141:36173624.
  • 69
    Milich DR, Schodel F, Hughes J, Jones JE, Peterson DL. The hepatitis B virus core and e antigen elicit different Th cell subsets: antigen structure can affect Th cell phenotype. J Virol 1997; 71:21922201.
  • 70
    Milich DR, Wolf SF, Hughes JL, Jones JE. Interleukin 12 suppresses autoantibody production by reversing helper T-cell phenotype in hepatitis B e antigen transgenic mice. Proc Natl Acad Sci U S A 1995; 92:68476851.
  • 71
    Milich DR, Chen M, Schodel F, Peterson DL, Jones JE, Hughes JL. Role of B cells in antigen presentation of the hepatitis B core. Proc Natl Acad Sci U S A 1997; 94:1464814653.
  • 72
    Reifenberg K, Deutschle T, Wild J, Hanano R, Gastrock-Balitsch I, Schirmbeck R, Schlicht HJ. The hepatitis B virus e antigen cannot pass the murine placenta efficiently and does not induce CTL immune tolerance in H-2b mice in utero. Virology 1998; 243:4553.
  • 73
    Milich DR, Jones JE, McLachlan A, Houghten R, Thornton GB, Hughes JL. Distinction between immunogenicity and tolerogenicity among HBcAg T cell determinants. Influence of peptide-MHC interaction. J Immunol 1989; 143:31483156.
  • 74
    Lin HH, Hsu HY, Chang MH, Chen PJ, Chen DS. Hepatitis B virus in the colostra of HBeAg-positive carrier mothers. J Pediatr Gastroenterol Nutr 1993; 17:207210.
  • 75
    Arakawa K, Tsuda F, Takahashi K, Ise I, Naito S, Kosugi E, Miyakawa Y, et al. Maternofetal transmission of IgG-bound hepatitis B e antigen. Pediatr Res 1982; 16:247250.
  • 76
    Lee SD, Lo KJ, Wu JC, Tsai YT, Wang JY, Ting LP, Tong MJ. Prevention of maternal-infant hepatitis B virus transmission by immunization: the role of serum hepatitis B virus DNA. Hepatology 1986; 6:369373.
  • 77
    Hsu HY, Chang MH, Hsieh KH, Lee CY, Lin HH, Hwang LH, Chen PJ, et al. Cellular immune response to HBcAg in mother-to-infant transmission of hepatitis B virus. Hepatology 1992; 15:770776.
  • 78
    Wang JS, Zhu QR. Infection of the fetus with hepatitis B e antigen via the placenta. Lancet 2000; 355:989.
  • 79
    Maruyama T, McLachlan A, Iino S, Koike K, Kurokawa K, Milich DR. The serology of chronic hepatitis B infection revisited. J Clin Invest 1993; 91:25862595.
  • 80
    Milich DR, Chen MK, Hughes JL, Jones JE. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol 1998; 160:20132021.
  • 81
    Milich DR, Jones J, Hughes J, Maruyama T. Role of T-cell tolerance in the persistence of hepatitis B virus infection. J Immunother 1993; 14:226233.
  • 82
    Baron JL, Gardiner L, Nishimura S, Shinkai K, Locksley R, Ganem D. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection. Immunity 2002; 16:583594.
  • 83
    Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4:2536.
  • 84
    Maruyama T, Iino S, Koike K, Yasuda K, Milich DR. Serology of acute exacerbation in chronic hepatitis B virus infection. Gastroenterology 1993; 105:11411151.
  • 85
    Maruyama T, Mitsui H, Maekawa H, Yamada H, Hirayama M, Iino S, Yasuda K, et al. Emergence of the precore mutant late in chronic hepatitis B infection correlates with the severity of liver injury and mutations in the core region. Am J Gastroenterol 2000; 95:28942904.
    Direct Link:
  • 86
    Ehata T, Omata M, Chuang WL, Yokosuka O, Ito Y, Hosoda K, Ohto M. Mutations in core nucleotide sequence of hepatitis B virus correlate with fulminant and severe hepatitis. J Clin Invest 1993; 91:12061213.
  • 87
    Ehata T, Omata M, Yokosuka O, Hosoda K, Ohto M. Variations in codons 84–101 in the core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis B virus infection. J Clin Invest 1992; 89:332338.
  • 88
    Milich DR, Schodel F, Peterson DL, Jones JE, Hughes JL. Characterization of self-reactive T cells that evade tolerance in hepatitis B e antigen transgenic mice. Eur J Immunol 1995; 25:16631672.
  • 89
    Chen M, Sallberg M, Thung SN, Hughes J, Jones J, Milich DR. Nondeletional T-cell receptor transgenic mice: model for the CD4(+) T-cell repertoire in chronic hepatitis B virus infection. J Virol 2000; 74:75877599.
  • 90
    Tsai SL, Chen PJ, Lai MY, Yang PM, Sung JL, Huang JH, Hwang LH, et al. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J Clin Invest 1992; 89:8796.
  • 91
    Diepolder HM, Ries G, Jung MC, Schlicht HJ, Gerlach JT, Grner N, Caselmann WH, et al. Differential antigen-processing pathways of the hepatitis B virus e and core proteins [see comments]. Gastroenterology 1999; 116:650657.
  • 92
    Xu J, Brown D, Harrison T, Lin Y, Dusheiko G. Absence of hepatitis B virus precore mutants in patients with chronic hepatitis B responding to interferon-alpha. Hepatology 1992; 15:10021006.
  • 93
    Kako M, Kanai K, Aikawa T, Iwabuchi S, Takehira Y, Kawasaki T, Tsubouchi H, et al. Response to interferon-alpha 2a in patients with e antigen-negative chronic hepatitis B. J Clin Gastroenterol 1997; 25:440445.
  • 94
    Fattovich G, Farci P, Rugge M, Brollo L, Mandas A, Pontisso P, Giustina G, et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992; 15:584589.
  • 95
    Pastore G, Santantonio T, Milella M, Monno L, Mariano N, Moschetta R, Pollice L. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J Hepatol 1992; 14:221225.
  • 96
    Lampertico P, Del Ninno E, Manzin A, Donato MF, Rumi MG, Lunghi G, Morabito A, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997; 26:16211625.
  • 97
    Alberti A, Fattovich G. Interferon therapy for the anti-HBe positive form of chronic hepatitis B. Antiviral Res 1994; 24:145153.
  • 98
    Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, Bonino F. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36:263270.
  • 99
    Manesis EK, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. Gastroenterology 2001; 121:101109.
  • 100
    Lin CC, Wu JC, Chang TT, Huang YH, Wang YJ, Tsay SH, Chow NH, et al. Long-term evaluation of recombinant interferon alpha2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan. J Viral Hepat 2001; 8:438446.
  • 101
    Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29:889896.
  • 102
    Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32:828834.
  • 103
    Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36:219226.
  • 104
    Chen RY, Edwards R, Shaw T, Colledge D, Delaney WET, Isom H, Bowden S, et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003; 37:2735.
  • 105
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348:800807.